OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the recipient of a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 32,380 shares, a decrease of 60.9% from the June 15th total of 82,735 shares. Based on an average trading volume of 64,916 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the company’s shares are sold short.

Key OKYO Pharma News

Here are the key news stories impacting OKYO Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on OKYO Pharma and maintained a $5.00 price target, signaling analyst confidence in the company’s longer-term potential. HC Wainwright rating and estimates
• Neutral Sentiment: The firm’s newly issued earnings estimates for FY2027, FY2028 and several quarterly periods all remain negative, underscoring that OKYO is still expected to operate at a loss for the foreseeable future. HC Wainwright earnings estimates
• Neutral Sentiment: OKYO Pharma said it will highlight its neuropathic corneal pain program at the Piper Sandler Virtual Ophthalmology Symposium, which could keep attention on its lead pipeline but does not represent a near-term commercial catalyst. OKYO Pharma symposium announcement

OKYO Pharma Trading Down 5.7%

Shares of OKYO stock traded down $0.09 during trading on Wednesday, reaching $1.49. The company’s stock had a trading volume of 547,052 shares, compared to its average volume of 169,026. OKYO Pharma has a 1-year low of $1.42 and a 1-year high of $3.35. The stock’s 50-day moving average price is $1.61 and its 200 day moving average price is $1.77.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on OKYO. HC Wainwright dropped their target price on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating for the company in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.67.

Hedge Funds Weigh In On OKYO Pharma

Several institutional investors have recently modified their holdings of OKYO. Renaissance Technologies LLC raised its stake in shares of OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after acquiring an additional 96,800 shares in the last quarter. XTX Topco Ltd purchased a new position in OKYO Pharma in the fourth quarter valued at $36,000. Finally, Citadel Advisors LLC acquired a new position in OKYO Pharma during the 3rd quarter worth $31,000. Institutional investors and hedge funds own 2.97% of the company’s stock.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.